Low sodium levels have been associated with negative outcomes among patients with metastatic renal cell carcinoma (mRCC) receiving therapies other than immune checkpoint inhibitors (ICIs).
To investigate the role of natremia in patients with mRCC receiving nivolumab as a second-line or subsequent therapy.
In this retrospective cohort study, the clinical and biochemical data of patients with mRCC receiving nivolumab were collected from October 2015 to November 2019 as part of a multicenter Italian study. Data analysis was performed from February to March 2023.
Nivolumab was administered intravenously at a dose of 3 mg/kg every 2 weeks and, since May 2018, at a fixed dose of 240 mg every 2 weeks or 480 mg every 4 weeks. Patients were divided into 2 groups according to their median serum sodium value (<140 or ≥140 mEq/L).
The primary outcomes were the associations of pre-ICI and post-ICI sodium levels with overall survival (OS), progression-free survival (PFS), objective response rate, and disease control rate (DCR). The Kaplan-Meier method was used to estimate PFS and OS, and differences between groups were compared using the log-rank test.
A total of 401 patients with mRCC receiving nivolumab as second-line therapy were evaluated, and 355 eligible patients (median [range] age, 76 [44-84] years; 258 male patients [72.7%]) were included in the final cohort. Among patients with pre-ICI sodium greater than or equal to 140 mEq/L compared with those with sodium less than 140 mEq/L, the median PFS was 9.3 months (95% CI, 6.5-11.5 months) vs 7.4 months (95% CI, 4.6-10.1 months; P = .90), and the median OS was 29.2 months (95% CI, 21.8-35.9 months) vs 20.0 months (95% CI, 14.1-26.8 months; P = .03). Patients with post-ICI sodium values greater than or equal to 140 mEq/L had longer PFS (11.1 months [95% CI, 8.5-1.5 months] vs 5.1 months [95% CI, 4.1-7.5 months]; P = .01) and OS (32.9 months [95% CI, 25.1-42.6 months] vs 17.1 months [95% CI, 12.6-24.5 months]; P = .006) compared with patients with sodium values less than 140 mEq/L. Patients with both pre-ICI and post-ICI sodium values greater than or equal to 140 mEq/L exhibited a significant improvement in clinical outcomes compared with those with a value less than 140 mEq/L (PFS, 11.5 months [95% CI, 8.8-16.4 months] vs 5.8 months [95% CI, 4.4-8.3 months]; P = .008); OS, 37.6 months [95% CI, 29.0-49.9 months] vs 19.4 months [95% CI, 14.1-24.5 months]; P = .01). Moreover, sodium levels greater than or equal to 140 mEq/L were associated with significantly better DCR than lower sodium levels.
In this retrospective cohort study of patients with mRCC receiving nivolumab, sodium values greater than or equal to 140 mEq/L, both before and/or after ICI, were associated with better OS and PFS, as well as a higher DCR, compared with levels less than 140 mEq/L. These findings suggest that sodium levels may be associated with survival outcomes in patients with mRCC and may have potential use as variables to consider in patients' risk scores.
JAMA network open. 2023 Nov 01*** epublish ***
Martina Catalano, Sara Elena Rebuzzi, Marco Maruzzo, Ugo De Giorgi, Sebastiano Buti, Luca Galli, Giuseppe Fornarini, Paolo Andrea Zucali, Giuseppe Procopio, Silvia Chiellino, Michele Milella, Fabio Catalano, Stefania Pipitone, Riccardo Ricotta, Mariella Sorarù, Veronica Mollica, Marianna Tudini, Lucia Fratino, Veronica Prati, Orazio Caffo, Francesco Atzori, Franco Morelli, Giuseppe Prati, Franco Nolè, Francesca Vignani, Alessia Cavo, Marilena Di Napoli, Andrea Malgeri, Emanuele Naglieri, Alessio Signori, Giuseppe Luigi Banna, Pasquale Rescigno, Lorenzo Antonuzzo, Giandomenico Roviello
Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Firenze, Firenze, Italy., Medical Oncology Unit, Ospedale San Paolo, Savona, Italy., Oncology 1 Unit, Department of Oncology, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy., Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, Meldola, Italy., Medical Oncology Unit, University Hospital of Parma, Parma, Italy., Medical Oncology Unit 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy., Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino of Genova, Genova, Italy., Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milano, Italy., SS Oncologia Medica Genitourinaria, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Medical Oncology Unit, IRCCS Policlinico San Matteo, Pavia, Italy., Section of Innovation Biomedicine-Oncology Area, Department of Engineering for Innovation Medicine, University of Verona and Verona University and Hospital Trust, Verona, Italy., Medical Oncology Unit, Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy., Oncology Unit, IRCCS MultiMedica, Sesto san Giovanni, Milano, Italy., U.O. Oncologia, Ospedale di Camposampiero, Camposampiero, Italy., Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy., Medical Oncology, St Salvatore Hospital, L'Aquila, Italy., Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano CRO-IRCCS, Aviano, Italy., Medical Oncology Unit, ASL CN 2, Alba-Bra, Italy., Department of Medical Oncology, Santa Chiara Hospital, Trento, Italy., Medical Oncology Department, University Hospital, University of Cagliari, Cagliari, Italy., Medical Oncology Department, Casa Sollievo Della Sofferenza Hospital, IRCCS, San Giovanni Rotondo, Italy., Department of Oncology and Advanced Technologies AUSL-IRCCS Reggio Emilia, Reggio Emilia, Italy., Medical Oncology Division of Urogenital & Head & Neck Tumors, IEO, European Institute of Oncology IRCCS, Milano, Italy., Division of Medical Oncology, Ordine Mauriziano Hospital, Torino, Italy., Oncology Unit, Villa Scassi Hospital, Genova, Italy., Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy., Department of Medical Oncology, Fondazione Policlinico Campus Bio-Medico, Roma, Italy., Division of Medical Oncology, IRCCS Istituto Tumori Giovanni Paolo II, Bari, Italy., Department of Health Sciences, Section of Biostatistics, University of Genova, Genova, Italy., Portsmouth Hospitals University NHS Trust, Portsmouth, United Kingdom., Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy., Medical Oncology, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.